STOCK TITAN
  1. Home
  2. News
  3. ENLV

Enlivex Therapeutics Ltd. Ordinary Shares - ENLV STOCK NEWS

Welcome to our dedicated page for Enlivex Therapeutics Ltd. Ordinary Shares news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics Ltd. Ordinary Shares stock.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage immunotherapy company focused on developing innovative allogeneic drugs to rebalance the immune system. The company's flagship product candidate, Allocetra™, is under development for multiple severe and critical conditions.

Allocetra™ is currently in a Phase IIB clinical trial targeting patients with severe sepsis, a life-threatening condition caused by the body's response to infection. Additionally, it is being investigated in a Phase II clinical trial for the treatment of COVID-19 patients with severe and critical conditions. The company is also exploring Allocetra™ in a Phase IIA trial for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplants (HSCT).

Enlivex is advancing Allocetra™ as a potential treatment for complications associated with bone marrow transplants, acute multiple organ failure, and as a combination therapy with various anti-cancer treatments to enhance efficacy. The immunotherapy works by reprogramming macrophages to their homeostatic state, thus rebalancing the immune system.

Recently, the Israeli Ministry of Health authorized a new trial for Allocetra™ targeting osteoarthritis, a chronic inflammatory condition affecting millions worldwide. This multi-country, double-blind, placebo-controlled Phase I/II trial aims to evaluate the safety and efficacy of Allocetra™ injections in knee osteoarthritis patients.

The company has shown promising results in its Phase II study of Allocetra™ in sepsis patients, demonstrating a favorable safety profile and potential effectiveness. With approvals from the Danish Medicines Agency and other international regulators, Enlivex is extending its clinical trials across multiple countries to further evaluate Allocetra™'s broad therapeutic potential.

News

Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) launches a new trial for AllocetraTM, a cell therapy to treat osteoarthritis in the knee. The therapy aims to reprogram macrophages and rebalance the immune microenvironment. The trial, authorized by the Israeli Ministry of Health, will evaluate efficacy, safety, and tolerability in up to 160 patients. This innovative approach could provide a new option for patients suffering from knee osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
clinical trial
-
News

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) is developing AllocetraTM, a cell therapy for sepsis treatment. The phase 2 trial of AllocetraTM has enrolled all 120 patients and is expected to release data by Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
clinical trial
-
News

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) has received a new patent, US 11,883,429, from the U.S. Patent and Trademark Office for its immunotherapy product candidate, AllocetraTM. The patent provides additional intellectual property protection for the product's composition and manufacturing method in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
none
News

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the authorization from the Israeli Ministry of Health for a multi-country Phase I/II trial to evaluate the efficacy, safety, and tolerability of Allocetra™ injections into the target knee joint of up to 160 moderately to severely symptomatic osteoarthritis patients. The trial will consist of a safety run-in, open-label dose escalation phase, followed by a double-blind, randomized, placebo-controlled stage. The primary measurements will assess joint-pain and joint-function compared to placebo at three months, six months, and 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
clinical trial
-
News

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) completes enrollment in Phase II trial for Allocetra™ in patients with sepsis. Topline data expected in late Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.96%
Tags
clinical trial
-
News

Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results

Rhea-AI Summary
Enlivex focuses on inflammatory and autoimmune indications, initiates clinical program in osteoarthritis, and plans to seek external collaborations for oncology assets. Workforce reduction of approximately 50% expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.73%
Tags
earnings
News

Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Enlivex Therapeutics to present corporate update at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
News

Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
clinical trial covid-19
-
News

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Rhea-AI Summary
Enlivex Therapeutics has announced that the first patient has been dosed under the amended protocol for the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. The amended protocol allows a higher SOFA score inclusion range, allowing the recruitment of patients with higher levels of sepsis severity. The protocol also provides for two cohorts (treatment and placebo) instead of four, streamlining the trial. The company expects the top-line data readout from the Phase II trial to be in Q1 2024, consistent with their previously announced timeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
clinical trial
News

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
earnings

FAQ

What is the current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?

The current stock price of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) is $1.07 as of November 15, 2024.

What is the market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)?

The market cap of Enlivex Therapeutics Ltd. Ordinary Shares (ENLV) is approximately 22.7M.

What is Enlivex Therapeutics Ltd.?

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage immunotherapy company developing allogeneic drugs to rebalance the immune system.

What is Allocetra™?

Allocetra™ is Enlivex's flagship immunotherapy candidate, designed to reprogram macrophages and rebalance the immune system. It is being tested for severe sepsis, COVID-19, GVHD, and more.

What clinical trials are ongoing for Allocetra™?

Allocetra™ is in Phase IIB trials for severe sepsis, Phase II for COVID-19, and Phase IIA for GVHD prevention. Additionally, it's being tested in a Phase I/II trial for knee osteoarthritis.

What recent achievements has Enlivex made?

Enlivex received approval from the Israeli Ministry of Health for a new osteoarthritis trial and announced positive Phase II study results for Allocetra™ in sepsis patients.

What is the significance of Allocetra™ in osteoarthritis treatment?

Allocetra™ is being evaluated for its potential to reprogram macrophages and address the inflammatory causes of osteoarthritis, offering a novel treatment option.

How does Allocetra™ work?

Allocetra™ works by restoring macrophages to their homeostatic state, helping to rebalance the immune system and treat various severe and chronic conditions.

What are the benefits of Enlivex's therapy?

Enlivex's Allocetra™ offers a potential new mechanism of action for treating life-threatening and debilitating conditions by modulating the immune system.

What is the company's financial condition?

Enlivex recently closed a $5 million registered direct offering, indicating strong financial support for its ongoing and future clinical trials.

What are the future plans for Allocetra™?

Enlivex plans to continue expanding its clinical trials for Allocetra™, including potential larger studies for sepsis and ongoing trials for knee osteoarthritis.

Where can I find more information about Enlivex?

For more details, visit Enlivex's official website at http://www.enlivex.com.

Stock ENLV logo
Enlivex Therapeutics Ltd. Ordinary Shares

Nasdaq:ENLV

ENLV Rankings

#5228 Ranked by Market Cap
N/A Ranked by Dividends

ENLV Stock Data

22.69M
21.41M
5.74%
16.73%
0.47%
Biotechnology
Healthcare
Link
United States of America
Ness Ziona